Morphic looks to justify “oral Entyvio” excitement

Morphic’s share price has enjoyed quite the run-up of late, climbing over 60% since the start of this year. The reason is growing investor enthusiasm about the group’s sole clinical asset, MORF-057, the results of whose Emerald-1 trial will likely be revealed during the second quarter.